Novartis Ag (NVSEF) Cash from Investing Activities Growth (1y) (2010 - 2025)
Novartis Ag (NVSEF) Cash from Investing Activities Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
-37.17% |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
-16.79% |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
-250.17% |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
21.90% |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-586.62% |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
-60.18% |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
526.51% |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
-76.02% |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
73.75% |
| 10 |
Novartis Ag |
- |
- |
- |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
48.76% |
| Sep 30, 2025 |
-129.95% |
| Jun 30, 2025 |
30.06% |
| Mar 31, 2025 |
136.71% |
| Dec 31, 2024 |
-142.13% |
| Jun 30, 2024 |
-234.06% |
| Mar 31, 2024 |
-435.12% |
| Dec 31, 2023 |
530.62% |
| Jun 30, 2023 |
91.74% |
| Dec 31, 2022 |
-356.29% |
| Jun 30, 2022 |
-11,965.31% |
| Dec 31, 2021 |
254.64% |
| Jun 30, 2021 |
123.06% |
| Dec 31, 2020 |
-252.27% |
| Jun 30, 2020 |
-304.33% |
| Dec 31, 2019 |
-25.45% |
| Jun 30, 2019 |
-95.50% |
| Dec 31, 2018 |
151.17% |
| Sep 30, 2018 |
-8.68% |
| Jun 30, 2018 |
1,656.23% |
